Comparative Genomic Analysis of PIK3R1-mutated and Wild-type Breast Cancers

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2023 Dec 28

PMID 38153569

Authors

Melody A Cobleigh

Kayla Viets Layng

Elizabeth Mauer

Brett Mahon

Adam J Hockenberry

Abde M Abukhdeir

Affiliations

Soon will be listed here.

Abstract

Purpose: The PIK3R1 gene encodes the regulatory subunit-p85a-of the PI3K signaling complex. Prior studies have found that pathogenic somatic alterations in PIK3R1 are enriched in human breast cancers but the genomic landscape of breast cancer patients harboring PIK3R1 mutations has not been extensively characterized.

Methods: We retrospectively analyzed 6,009 patient records that underwent next-generation sequencing (NGS) using the Tempus xT solid tumor assay. All patients had breast cancer with known HER2 (+/-) and hormone receptor (HR; +/-) status and were classified according to the presence of PIK3R1 mutations including short variants and copy number alterations.

Results: The frequency of PIK3R1 mutations varied according to subtype: 6% in triple negative (TNBC, 89/1,475), 2% in HER2-/HR+ (80/3,893) and 2.3% in HER2+ (15/641) (p < 0.001). Co-mutations in PTEN, TP53 and NF1 were significantly enriched, co-mutations in PIK3CA were significantly less prevalent, and tumor mutational burden was significantly higher in PIK3R1-mutated HER2- samples relative to PIK3R1 wild-type. At the transcriptional-level, PIK3R1 RNA expression in HER2- disease was significantly higher in PIK3R1-mutated (excluding copy number loss) samples, regardless of subtype.

Conclusion: This is the largest investigation of the PIK3R1 mutational landscape in breast cancer patients (n = 6,009). PIK3R1 mutations were more common in triple-negative breast cancer (~ 6%) than in HER2 + or HER2-/HR + disease (approximately 2%). While alterations in the PI3K/AKT pathway are often actionable in HER2-/HR + breast cancer, our study suggests that PIK3R1 could be an important target in TNBC as well.

Citing Articles

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.

Unveiling the Bioactive Efficacy of 'Stricta' Essential Oil: Composition, In Vitro Activities, and In Silico Analyses.

Fikry E, Orfali R, Tawfeek N, Perveen S, Ghafar S, El-Domiaty M Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204124 PMC: 11357629. DOI: 10.3390/ph17081019.

References

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

Cheung L, Hennessy B, Li J, Yu S, Myers A, Djordjevic B . High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 1(2):170-85. PMC: 3187555. DOI: 10.1158/2159-8290.CD-11-0039. View

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

Park S, Kang M, Eom H, Han J, Ahn C, Kim S . Somatic mutation of PIK3R1 gene is rare in common human cancers. Acta Oncol. 2009; 49(1):125-7. DOI: 10.3109/02841860903107890. View

Mizoguchi M, Nutt C, Mohapatra G, Louis D . Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004; 14(4):372-7. PMC: 8095817. DOI: 10.1111/j.1750-3639.2004.tb00080.x. View

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

Wood L, Parsons D, Jones S, Lin J, Sjoblom T, Leary R . The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318(5853):1108-13. DOI: 10.1126/science.1145720. View

Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D . PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer. 2013; 13:545. PMC: 4225603. DOI: 10.1186/1471-2407-13-545. View

Thorpe L, Spangle J, Ohlson C, Cheng H, Roberts T, Cantley L . PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proc Natl Acad Sci U S A. 2017; 114(27):7095-7100. PMC: 5502636. DOI: 10.1073/pnas.1704706114. View

10.

Turturro S, Najor M, Yung T, Portt L, Malarkey C, Abukhdeir A . Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway. Breast Cancer Res Treat. 2019; 177(2):325-333. DOI: 10.1007/s10549-019-05320-x. View

11.

Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R . Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019; 37(11):1351-1360. DOI: 10.1038/s41587-019-0259-z. View

12.

Beaubier N, Tell R, Lau D, Parsons J, Bush S, Perera J . Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019; 10(24):2384-2396. PMC: 6481324. DOI: 10.18632/oncotarget.26797. View

13.

Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

14.

Bray N, Pimentel H, Melsted P, Pachter L . Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016; 34(5):525-7. DOI: 10.1038/nbt.3519. View

15.

Urick M, Rudd M, Godwin A, Sgroi D, Merino M, Bell D . PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011; 71(12):4061-7. PMC: 3117071. DOI: 10.1158/0008-5472.CAN-11-0549. View

16.

Quayle S, Lee J, Cheung L, Ding L, Wiedemeyer R, Dewan R . Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 2012; 7(11):e49466. PMC: 3498106. DOI: 10.1371/journal.pone.0049466. View

17.

Chagpar R, Links P, Pastor M, Furber L, Hawrysh A, Chamberlain M . Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 2010; 107(12):5471-6. PMC: 2851819. DOI: 10.1073/pnas.0908899107. View

18.

Sjoblom T, Jones S, Wood L, Parsons D, Lin J, Barber T . The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314(5797):268-74. DOI: 10.1126/science.1133427. View

19.

Jaiswal B, Janakiraman V, Kljavin N, Chaudhuri S, Stern H, Wang W . Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009; 16(6):463-74. PMC: 2804903. DOI: 10.1016/j.ccr.2009.10.016. View

20.

Kan Z, Jaiswal B, Stinson J, Janakiraman V, Bhatt D, Stern H . Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-73. DOI: 10.1038/nature09208. View